Hints and tips:
Related Special Reports
...Bristol Myers Squibb raised $13bn in a large bond deal on Wednesday that will help fund two acquisitions....
...Bristol Myers Squibb launched a potentially jumbo-sized bond deal on Wednesday to help fund two acquisitions....
...Bristol Myers Squibb has agreed to buy neuroscience biotech Karuna Therapeutics for $14bn, gaining access to a promising schizophrenia drug....
...Bristol Myers Squibb has pushed out by one year its sales target for a new crop of drugs, guiding that the pharmaceutical company’s goal of at least $10bn would now not be achieved until 2026....
...Still, that has not stopped investors from fretting about pipeline replacement at companies such as Bristol Myers Squibb (BMS), Sanofi and Roche....
...Earnings: Aon, Bristol Myers Squibb, Danske Bank, Deutsche Bank, Electrolux, Ferrari and YouGov release results. Economic data: Monthly industrial production figures are to be published in France....
...Pharmaceutical company Bristol Myers Squibb fell 3.5 per cent after the federal US drug regulator delayed its decision to expand the use of a cancer therapy and as rival Bayer stopped a late-stage study...
...Pharma: Pharmaceutical groups Bristol Myers Squibb, Regeneron and AbbVie will also report earnings before the market opens....
...The impact could be significant for companies such as Bristol Myers Squibb. Its blood thinner Eliquis is expected to account for more than a quarter of sales in 2026, according to Visible Alpha....
...A price to forward earnings multiple of over 50 values the stock more like a tech company than a pharma group. Bristol Myers Squibb trades on just seven times earnings while Pfizer is on 20 times....
...Oxford-based Exscientia is working with Sanofi and Bristol Myers Squibb, among others, and Insitro has a deal with Bristol Myers, while Owkin is also collaborating with Sanofi....
...High-grade pharma group Bristol Myers Squibb sold $13bn of debt on Wednesday....
...Mirati, which was purchased by Bristol Myers Squibb in a deal announced last year, did not immediately respond to a request for comment....
...Other earnings: Merck, Bristol Myers Squibb, UPS, Northrop Grumman, Honeywell, Altria, Hershey, Mastercard and Royal Caribbean report earnings before the opening bell....
...Bristol Myers Squibb said on Wednesday that chief executive Giovanni Caforio would step down as chief executive on November 1 and be replaced by chief commercialisation officer Christopher Boerner....
...Myers Squibb would buy the biotech company....
...Other drugmakers including Merck, Bristol Myers Squibb, and Johnson & Johnson, as well as the US pharmaceutical lobby group, have already filed lawsuits against the reforms....
...In the pharmaceutical industry, big companies including AstraZeneca, AbbVie and Bristol Myers Squibb have announced about $25bn worth of biotech-related deals....
...Pharmaceutical groups Bristol Myers Squibb, Regeneron and AbbVie are also expected to release earnings....
...The company joins Merck, Bristol Myers Squibb and the lobby group Pharmaceutical Research and Manufacturers of America in challenging the new law....
...Johnson & Johnson joins the Merck, Bristol Myers Squibb and pharmaceutical lobby Pharmaceutical Research and Manufacturers of America in challenging the new law....
...Bristol Myers Squibb told the FT last year it expected to cancel some drug programmes, with cancer medicines most vulnerable....
...They include Eliquis, a blood thinner produced by Bristol Myers Squibb (BMS) and its partner Pfizer, the diabetes treatment Jardiance sold by Boehringer Ingelheim and Eli Lilly, and Xarelto, another blood...
International Edition